 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Generation Bio Co. (NASDAQ:GBIO  Free Report)  Equities researchers at Wedbush raised their FY2023 EPS estimates for shares of Generation Bio in a research note issued to investors on...

FY2023 EPS Estimates for Generation Bio Co. Increased by Analyst (NASDAQ:GBIO)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Generation Bio announces strategic reorganization

Company to invest in highly selective cell-targeted lipid nanoparticle (ctLNP) delivery platform to develop wholly-owned programs for extrahepatic cell typesDevelopment of immune-quiet DNA (iqDNA...

Generation Bio Announces Strategic Reorganization to Extend Cash Runway for Development of ctLNP and iqDNA Platforms

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Hold rating on Generation Bio (GBIO Research Report). The company's...

JMP Securities Keeps Their Hold Rating on Generation Bio (GBIO)

Generation Bio (NASDAQ:GBIO  Get Free Report) had its price target dropped by stock analysts at Wedbush from $11.00 to $9.00 in a research note issued on Friday, Benzinga reports. The firm...

Wedbush Lowers Generation Bio (NASDAQ:GBIO) Price Target to $9.00

JMP Securities analyst Silvan Tuerkcan has maintained their neutral stance on GBIO stock, giving a Hold rating yesterday. Silvan Tuerkcan provided...

Hold Rating on Generation Bio: Innovations in Immune-Quiet DNA and ctLNP Delivery System Yet Uncertain Timeline for Hemophilia A Program

TD Cowen analyst Yaron Werber maintained a Hold rating on Generation Bio (GBIO Research Report) yesterday. The company's shares closed yesterday...

Generation Bio (GBIO) Gets a Hold from TD Cowen

- Immune-quiet DNA evades innate immune sensors in both mice and non-human primates addressing a central challenge for non-viral DNA therapeutics - Proprietary cell-targeted LNP delivery system...

Generation Bio Reports Business Highlights and Third Quarter 2023 Financial Results

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Generation Bio (GBIO Research Report) and Regenero...

Analysts Are Bullish on These Healthcare Stocks: Generation Bio (GBIO), Regeneron (REGN)

Generation Bio to host research and development meeting

Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA, a novel cell-targeted lipid nanoparticle delivery system, or ctLNP, and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

Market Cap	$109.69M
Volume (M)	291,198.00
52-Wk High	$7.35
52-Wk Low	$0.86

GBIO Generation Bio Co

About

Feed

News

Sentiment

Earnings

Fundamentals